The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Share News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.05
Bid: 2.01
Ask: 2.04
Change: -0.05 (-2.41%)
Spread: 0.03 (1.493%)
Open: 2.05
High: 2.09
Low: 2.00
Prev. Close: 2.075
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Fundraise lifts ImmuPharma; Proteome wins deal

Mon, 20th Dec 2021 11:41

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

----------

AIM - WINNERS

----------

ImmuPharma PLC, up 27% at 7.72 pence, 12-month range 4.80p-13.85p. The drug discovery and development company completes GBP3.6 million fundraise via placing and subscription of 32.3 million shares at 11.00 pence each. This is an 80% premium to Friday's closing price of 6.10p. Additionally, ImmuPharma secures a GBP2.2 million subscription from investment firm Lanstead.

----------

Proteome Sciences PLC, up 6.1% to 5.20p, 12-month range 3.07p-10.00p. The drug development services provider wins a new contract in excess of GBP1 million from an unnamed "major pharmaceutical company". Under the terms of the contract, Proteome will analyse large cohorts of clinical samples from a phase 3 clinical trial. Work is expected to start early in the first quarter of 2022

----------

AIM - LOSERS

----------

ThinkSmart Ltd, down 21% at 64.22p, 12-month range 51.00p-115.00p. The Australian digital payments platform reaches an agreement with Afterpay to sell its remaining 10% stake in Clearpay in exchange for 1.7 million shares in Afterpay, worth GBP73.4 million. The disposal will be put to a vote of ThinkSmart shareholders at a meeting on January 14, it adds.

----------

Hurricane Energy PLC, down 14% at 3.60p, 12-month range 0.59p-5.30p. The oil and gas company completes a review into events that led to the rejection of its restructuring plan by the High Court of Justice of England & Wales. The review, overseen by Hurricane's non-executive directors and carried out by an independent solicitor, found that the company's prior board "discharged their fiduciary duties diligently and in good faith". The non-executive directors have agreed following the review that no further action is necessary, and that time and resources should now go towards maximising the future revenue and potential of the company.

----------

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
22 Sep 2020 21:17

IN BRIEF: Immupharma Repays Lind Global Convertible Security

IN BRIEF: Immupharma Repays Lind Global Convertible Security

Read more
11 Sep 2020 14:09

IN BRIEF: Immupharma Still Awaiting FDA Reply For Lupuzor Submission

IN BRIEF: Immupharma Still Awaiting FDA Reply For Lupuzor Submission

Read more
11 Sep 2020 12:17

ImmuPharma confirms continued FDA delays for Lupuzor

(Sharecast News) - Specialist drug discovery and development company ImmuPharma on its special protocol assessment (SPA) submission to the US Food and Drug Administration (FDA) for the phase 3 trial of 'Lupuzor' in lupus patients.

Read more
2 Sep 2020 11:18

Immupharma Raises GBP6.5 Million In Oversubscribed Placing

Immupharma Raises GBP6.5 Million In Oversubscribed Placing

Read more
2 Sep 2020 09:25

Immupharma raises £6.5m in oversubscribed placing

(Sharecast News) - Drug discovery and development firm Immupharma has raised £6.5m, before fees, via an oversubscribed placing of 59.09m ordinary shares.

Read more
27 Jul 2020 17:50

IN BRIEF: ImmuPharma Partner Avion Submits Request To FDA For Lupuzor

IN BRIEF: ImmuPharma Partner Avion Submits Request To FDA For Lupuzor

Read more
27 Jul 2020 15:15

ImmuPharma clears 'important' regulatory hurdle for Lupuzor trial

(Sharecast News) - Specialist drug discovery and development company ImmuPharma announced what it called "an important regulatory milestone" on Monday, in preparation for the new optimised international phase 3 trial of 'Lupuzor' for the autoimmune disease systemic lupus erythematosus.

Read more
11 Jun 2020 16:17

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
11 Jun 2020 13:53

Immupharma Gets Over USD6 Million Investment From US Healthcare Funds

Immupharma Gets Over USD6 Million Investment From US Healthcare Funds

Read more
14 May 2020 17:13

UK TRADING UPDATE SUMMARY: Byotrol Sees Continuation Of Strong Demand

UK TRADING UPDATE SUMMARY: Byotrol Sees Continuation Of Strong Demand

Read more
1 May 2020 09:51

ImmuPharma Annual Loss Narrows; Plans "Optimised" Lupuzor Trial

ImmuPharma Annual Loss Narrows; Plans "Optimised" Lupuzor Trial

Read more
31 Mar 2020 07:31

ImmuPharma Raises GBP1.5 Million Through Share Issue To Fund Expansion

ImmuPharma Raises GBP1.5 Million Through Share Issue To Fund Expansion

Read more
30 Mar 2020 16:18

ImmuPharma raises ?1.5m to fund development programmes

(Sharecast News) - Drug discovery and development company ImmuPharma announced subscriptions to raise ?1.5m through the issue of 15 million new ordinary shares at a price of 10p each on Monday.

Read more
28 Feb 2020 12:06

Immupharma Inks Subscription Agreement Amid Incanthera's NEX Float

Immupharma Inks Subscription Agreement Amid Incanthera's NEX Float

Read more
6 Feb 2020 15:54

ImmuPharma and Avion to proceed with Lupuzor phase 3 trial

(Sharecast News) - Specialist drug discovery and development company ImmuPharma updated the market on its activities with Avion Pharmaceuticals on Thursday, following the licence and development agreement it signed with Avion in November for the exclusive rights to 'Lupuzor' in North America.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.